ASO Author Reflections: Patient-Reported Outcomes of the CAIRO6 Phase II Trial

Résumé fourni par la source

PASTCytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been recommended in most (inter)national guidelines for selected patients with colorectal peritoneal metastases (CPM). 1 While the additional benefit of HIPEC after CRS is currently a topic of discussion, there is also no consensus on the role of perioperative systemic therapy in addition to CRS/HIPEC for resectable CPM.As a result, the administration and timing of perioperative systemic therapy in this patient group is heterogenous worldwide, and insight into its efficacy and burden is lacking. 2 In the absence of clinical trials investigating this topic, the CAIRO6 trial was commenced in 2017.3 This investigator-initiated, parallelgroup, open-label, phase II/III, superiority trial randomizes patients with resectable CPM to upfront CRS/HIPEC alone or CRS/HIPEC with perioperative systemic therapy.As part of the phase II trial, patient-reported outcomes (PROs) were compared between both treatment groups to evaluate the burden of perioperative systemic therapy in this setting.4

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.